Abstract 305P
Background
The prognosis in patients with breast cancer with isolated locoregional recurrence (ILRR) without simultaneous distant metastases after immediate breast reconstruction (IBR) remains unknown. We aimed to investigate the prognosis in this patient population.
Methods
This multi-institutional retrospective observational study evaluated 3,295 patients with primary breast cancer who underwent IBR at 12 Japanese medical facilities between January 1, 2008 and December 31, 2016. The outcome measures were the prognostic factors for ILRR after IBR, 5-year distant metastasis-free survival (DMFS), and 5-year overall survival (OS).
Results
Mastectomy or skin-sparing mastectomy was performed in 3,295 patients. ILRR occurred in 70 patients, and the median observation period from ILRR diagnosis was 39.3 months. Of the 70 patients, 9 (12.9%) had axillary lymph node recurrence (ALNR) at the time of ILRR diagnosis. The 5-year DMFS after ILRR was 92.4%. Patients with ILRR who had ALNR had a significantly worse DMFS than that had by those without ALNR (P = 0.005).The 5-year OS after ILRR was 91.2%. Patients with ILRR who had ALNR had a significantly worse OS than that had by those without ALNR (P = 0.005).The relationship between DMFS and clinicopathological factors was analyzed using the Cox proportional hazards model. Univariate analysis revealed significant associations of pN at primary surgery (P = 0.041) and ALNR at ILRR (HR: 9.960, 95% CI: 1.400–70.862, P = 0.022) with DMFS. However, ALNR was the only independent prognostic factor for DMFS in the multivariate analysis (P = 0.041). Univariate analysis revealed significant associations of post-mastectomy radiation therapy (PMRT) at primary surgery (P = 0.023) and ALNR at ILRR (P = 0.043) with OS. In multivariate analysis, both PMRT (P = 0.010) and ALNR (P = 0.028) were independent prognostic factors for OS.
Conclusions
Although patients with breast cancer who have ILRR after IBR have a favorable prognosis overall, ALNR at the diagnosis of ILRR may be a poor prognostic factor. Our results may contribute to developing strategies to predict prognosis in patients with breast cancer who develop ILRR after IBR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
334P - Cardiovascular events related to CDK4/6 inhibitors: A systematic review and safety meta-analysis of randomized controlled trials
Presenter: Louis Boismoreau
Session: Poster session 14
335P - First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 14
336P - Determination of the most common hereditary mutations associated with breast cancer and ovarian cancer in the population of Ukrainian women
Presenter: Dmytro Nehrulia
Session: Poster session 14
337P - Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?
Presenter: Jennifer Chen
Session: Poster session 14
338TiP - EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Presenter: Michail Ignatiadis
Session: Poster session 14
339TiP - A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Presenter: Theodoros Foukakis
Session: Poster session 14
351P - Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial
Presenter: Giampaolo Bianchini
Session: Poster session 14
352P - Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03)
Presenter: Noor Wortelboer
Session: Poster session 14
353P - Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Presenter: Robert Scheel
Session: Poster session 14